Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 6/20 | 0.66 |
| ▸ | GSK3A | P49840 | 4/20 | 0.66 |
| ▸ | GSK3B | P49841 | 4/20 | 0.66 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CA4 | P22748 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.51 |
| ▸ | FAAH | O00519 | 4/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21291908 | 0.80 | MGLL (0.66) | MGLLGSK3AGSK3BCA1CA2 | |
| SCHEMBL20251099 | 0.80 | MGLL (0.66) | MGLLGSK3AGSK3BCA1CA2 | |
| SCHEMBL7542262 | 0.80 | MGLL (0.66) | MGLLGSK3AGSK3BCA1CA2 | |
| SCHEMBL19419960 | 0.80 | GSK3A (0.66) | MGLLGSK3AGSK3BCA1CA2 | |
| SCHEMBL14677902 | 0.80 | MGLL (0.66) | MGLLGSK3AGSK3BCA1CA2 | |
| SCHEMBL19555152 | 0.79 | MGLL (0.78) | MGLLGSK3AGSK3BCA1CA2 | |
| SCHEMBL211905 | 0.79 | GSK3A (1.00) | MGLLGSK3AGSK3BCA1CA2 | |
| SCHEMBL4154508 | 0.78 | ALDH1A1 (0.61) | CA1CA2CA4CA9ALDH1A1 | |
| SCHEMBL32665577 | 0.78 | CA1 (0.71) | MGLLGSK3AGSK3BCA1CA2 | |
| SCHEMBL20375568 | 0.76 | MGLL (0.65) | MGLLGSK3AGSK3BCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115197719-B | Liquid crystal aligning agent, liquid crystal alignment film, liquid crystal element and method for manufacturing liquid crystal element | JSR株式会社 | 2025-03-28 | — | — | CN | disclosed |
| CN-115197719-A | Liquid crystal aligning agent, liquid crystal alignment film, liquid crystal element, and method for producing same | JSR株式会社 | 2022-10-18 | — | — | CN | disclosed |
| US-20220064195-A1 | SYNTHETIC I2 IMIDAZOLINE RECEPTOR LIGANDS FOR PREVENTION OR TREATMENT OF HUMAN BRAIN DISORDERS | UNIVERSITAT DE LES ILLES BALEARS (ES) | 2022-03-03 | — | — | US | disclosed |
| EP-3897838-A1 | <SUP2/>? <SUB2/>?2?SYNTHETIC IIMIDAZOLINE RECEPTOR LIGANDS FOR PREVENTION OR TREATMENT OF HUMAN BRAIN DISORDERS | Universitat de Barcelona (ES) | 2021-10-27 | — | — | EP | disclosed |
| CN-105130995-B | Pyrrolidone compound and its preparation method and application | 杭州成邦医药科技有限公司 | 2017-08-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064195-A1 | SYNTHETIC I2 IMIDAZOLINE RECEPTOR LIGANDS FOR PREVENTION OR TREATMENT OF HUMAN BRAIN DISORDERS | CHRM1, GPR3, CHRM3 | MGLL 3253/4885GSK3A 2460/4885GSK3B 2454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.